Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 9/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.36 |
| ▸ | GRIA1 | P42261 | 3/20 | 0.36 |
| ▸ | ACKR3 | P25106 | 2/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
| ▸ | HRH2 | P25021 | 1/20 | 0.36 |
| ▸ | HRH1 | P35367 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
| ▸ | BTK | Q06187 | 1/20 | 0.35 |
| ▸ | MELK | Q14680 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3924839 | 0.87 | MAP4K4 (0.47) | PDE4APDE4BPDE4CPDE4DBTK | |
| SCHEMBL3927951 | 0.87 | MAP4K4 (0.47) | PDE4APDE4BPDE4CPDE4DBTK | |
| SCHEMBL8155298 | 0.79 | BPTF (0.44) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL8158083 | 0.79 | BPTF (0.44) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3931900 | 0.77 | PDE10A (0.42) | SMPD3 | |
| SCHEMBL3922080 | 0.75 | PDE4A (0.55) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4121554 | 0.75 | PDE4A (0.55) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3921361 | 0.75 | PDE4A (0.55) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4528382 | 0.74 | PDE4A (0.51) | PDE4APDE4BPDE4CPDE4DHRH4 | |
| SCHEMBL3921822 | 0.74 | PDE4A (0.49) | PDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090036430-A1 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MEDICAL TREATMENT | 4 AZA IP NV (BE) | 2009-02-05 | — | — | US | disclosed |
| US-20080004285-A1 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MEDICAL TREATMENT | 4 AZA IP NV (BE) | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004285-A1 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MEDICAL TREATMENT | PNPO, TYMP, PNP | PDE4A 112/4885PDE4B 313/4885PDE4C 158/4885 |
| US-20090036430-A1 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MEDICAL TREATMENT | PNPO, TYMP, PNP | PDE4A 112/4885PDE4B 313/4885PDE4C 158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.